MAWDBP1 inhibitors represent a class of chemical compounds that act by selectively inhibiting the activity of the MAWDBP1 protein. MAWDBP1, or "MEK1 and WDR domain binding protein 1," is involved in various cellular processes, particularly those regulating signal transduction pathways. These inhibitors typically function by interacting with the active or regulatory sites of the MAWDBP1 protein, thus modulating its ability to facilitate downstream signaling events. The inhibition of MAWDBP1 can disrupt its role in several intracellular mechanisms, such as protein-protein interactions, phosphorylation events, and the regulation of gene expression. Structurally, MAWDBP1 inhibitors tend to exhibit high specificity for the protein, often featuring hydrophobic or aromatic regions that facilitate binding to the protein's active site, along with polar groups that engage in hydrogen bonding or ionic interactions to stabilize the inhibitor-protein complex.
Research into the chemical properties of MAWDBP1 inhibitors has revealed the importance of optimizing their physicochemical characteristics to ensure stability and effective binding. Molecular modifications, such as the addition of bulky side chains or altering the rigidity of the core scaffold, are commonly employed to improve the selectivity and potency of these inhibitors. Furthermore, these compounds are often subjected to studies regarding their metabolic stability, solubility, and permeability to understand their behavior in biological systems. Such studies help determine the compounds' potential for further development and optimization. The understanding of how MAWDBP1 inhibitors interact at the molecular level provides insights into broader areas of chemical biology, such as the fine-tuning of protein inhibition, which is crucial for advancing the knowledge of protein function and regulation within cellular systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
A potent ATP-competitive inhibitor of TGF-β type I receptor (ALK5), thus affecting the TGF-β pathway. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Inhibits ALK5, ALK4, and ALK7, leading to the blockade of TGF-β signaling. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
Selectively inhibits ALK5, ALK4, and ALK7, disrupting TGF-β signaling. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
A potent inhibitor of ALK5 and ALK4, reducing TGF-β-induced responses. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-βR1 inhibitor, impacting TGF-β signaling and associated cellular processes. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
Inhibits ALK5, modifying TGF-β pathway and possibly affecting MAWDBP1-related processes. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
Selectively inhibits TGF-β receptor I, altering TGF-β-mediated signaling. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
A potent ALK5 inhibitor, impacting TGF-β signaling and related cellular responses. | ||||||
ITD 1 | 1099644-42-4 | sc-507349 | 10 mg | $220.00 | ||
Selective TGF-β pathway inhibitor, specifically targeting TGF-βR1. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
Inhibits ALK4, ALK5, and ALK7, leading to disruption of TGF-β signaling. | ||||||